Hot flashes: A review of pathophysiology and treatment modalities

Oncologist

Volumn 16, Issue 11, 2011, Pages 1658-1664

  Morrow, Phuong Khanh H ^a   Mattair, Danielle N ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hot flashes; Menopause; Quality of life; Therapy; Vasomotor symptoms

Indexed keywords

ALPHA TOCOPHEROL; ANASTROZOLE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; CITALOPRAM; CLONIDINE; ESTRADIOL; ESTROGEN; EXEMESTANE; FLUOXETINE; GABAPENTIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PAROXETINE; PHYTOESTROGEN; PLACEBO; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; VENLAFAXINE;

ACUPUNCTURE; ALPHA RHYTHM; ALTERNATIVE MEDICINE; BEHAVIOR MODIFICATION; BREAST CANCER; CANCER PATIENT; CONSTIPATION; DROWSINESS; ELECTROCARDIOGRAM; ESTROGEN THERAPY; EXERCISE; HORMONAL THERAPY; HOT FLUSH; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METASTASIS POTENTIAL; MUSCLE RELAXATION; MUSCLE STRETCHING; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTATE CANCER; RELAXATION TRAINING; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; THERMOREGULATION; VASOMOTOR DISORDER; XEROSTOMIA; YOGA;

BREAST NEOPLASMS; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MALE; MENOPAUSE; MIDDLE AGED; PROGESTINS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 82355187854     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0174     Document Type: Review

References (70)

1. Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health 2010;2: 123-135.
2. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med 2006;355: 2338-2347.
3. Dalal S, Zhukovsky DS. Pathophysiology and management of hot flashes. J Support Oncol 2006; 4:315-320, 325.
4. Kronenberg F. Hot flashes: Epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86; discussion 123-133.
5. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344: 1997-2008.
6. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353: 1993-2000.
7. Loprinzi CL, Zahasky KM, Sloan JA et al. Tamoxifen-induced hot flashes. Clin Breast Cancer 2000;1:52-56.
8. Love RR, Cameron L, Connell BL et al., Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151: 1842-1847.
9. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. The Oncologist 2004;9:126-136.
10. Paridaens RJ, Dirix LY, Beex LV et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-4890.
11. Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al.; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361: 766-776.
12. Cuzick J, Sestak I, Cella D et al.; ATAC Trialists' Group. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol 2008;9:1143-1148.
13. Koeberle D, Thuerlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat 2007;105:55-66.
14. Mar Fan HG, Houédé-Tchen N, Chemerynsky I et al. Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: A prospective controlled study. Ann Oncol 2010; 21:983-987.
15. Goodwin PJ, Ennis M, Pritchard KI et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-2370.
16. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with nodepositive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16:2651-2658.
17. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990;1:183-188.
18. Loprinzi CL, Dueck AC, Khoyratty BS et al. A phase III randomized, double-blind, placebocontrolled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 2009;20: 542-549.
19. Schow DA, Renfer LG, Rozanski TA et al. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998;91:855-857.
20. Charig CR, Rundle JS. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 1989;33:175-178.
21. Shanafelt TD, Barton DL, Adjei AA et al. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-1218.
22. Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. Am J Med 2005;118(suppl 12B):124-130.
23. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001;13:453-464.
24. Sturdee DW. The menopausal hot flushanything new? Maturitas 2008;60:42-49.
25. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-285.
26. Velie EM, Nechuta S, Osuch JR. Lifetime reproductive and anthropometric risk factors for breast cancer in postmenopausal women. Breast Dis 2005;24:17-35.
27. Bachmann GA, Schaefers M, Uddin A et al. Lowest effective transdermal 17β-estradiol dose for relief of hot flushes in postmenopausal women: A randomized controlled trial. Obstet Gynecol 2007;110:771-779.
28. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
29. Chlebowski RT, Anderson GL, Gass M et al., Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-1692.
30. LaCroix AZ, Chlebowski RT, Manson JE et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 2011;305:1305-1314.
31. Jungheim ES, Colditz GA. Short-term use of unopposed estrogen: A balance of inferred risks and benefits. JAMA 2011;305:1354-1355.
32. Steinberg KK, Thacker SB, Smith SJ et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265:1985-1990.
33. Loprinzi CL, Michalak JC, Quella SK et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-352.
34. Bertelli G, Venturini M, Del Mastro L et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: A randomized study. Ann Oncol 2002;13:883-888.
35. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-228.
36. Benster B, Carey A, Wadsworth F et al. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int 2009;15: 63-69.
37. Hofseth LJ, Raafat AM, Osuch JR et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-4565.
38. Schindler AE, Muller D, Keller E et al., Studies with clonidine (Dixarit) in menopausal women. Arch Gynecol 1979;227:341-347.
39. Clayden JR, Bell JW, Pollard P. Menopausal flushing: Double-blind trial of a non-hormonal medication. Br Med J 1974;1:409-412.
40. Laufer LR, Erlik Y, Meldrum DR et al. Effect of clonidine on hot flashes in postmenopausal women. Obst Gynecol 1982;60:583-586.
41. Goldberg RM, Loprinzi CL, O'Fallon JR et al. Transdermal clonidine for ameliorating tamoxifeninduced hot flashes. J Clin Oncol 1994;12:155-158.
42. Nelson HD, Vesco KK, Haney E et al. Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-analysis. JAMA 2006; 295:2057-2071.
43. Loprinzi CL, Barton DL, Sloan JA et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: A 20-year experience. Menopause 2008;15:655-660.
44. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583.
45. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet 2000;356:2059-2063.
46. Barton DL, LaVasseur BI, Sloan JA et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG Trial N05C9. J Clin Oncol 2010;28:3278-3283.
47. Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study. BMJ 2010;340:c693.
48. Loprinzi CL, Sloan J, Stearns V et al. Newer antidepressants and gabapentin for hot flashes: An individual patient pooled analysis. J Clin Oncol 2009;27:2831-2837.
49. Guttuso T Jr, Kurlan R, McDermott MP et al. Gabapentin's effects on hot flashes in postmenopausal women: A randomized controlled trial. Obstet Gynecol 2003;101:337-345.
50. Pandya KJ, Morrow GR, Roscoe JA et al. Gabapentin for hot flashes in 420 women with breast cancer: A randomised double-blind placebo-controlled trial. Lancet 2005;366:818-824.
51. Reddy SY, Warner H, Guttuso T Jr et al. Gabapentin, estrogen, and placebo for treating hot flushes: A randomized controlled trial. Obstet Gynecol 2006;108:41-48.
52. Bordeleau L, Pritchard KI, Loprinzi CL et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147-5152.
53. Loprinzi CL, Levitt R, Barton D et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006;24:1409-1414.
54. Loprinzi CL, Kugler JW, Barton DL et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 2007;25:308-312.
55. Barton DL, Loprinzi CL, Quella SK et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16:495-500.
56. Quella SK, Loprinzi CL, Barton DL et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group trial. J Clin Oncol 2000;18:1068-1074.
57. Walker EM, Rodriguez AI, Kohn B et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: A randomized controlled trial. J Clin Oncol 2010;28: 634-640.
58. Harding C, Harris A, Chadwick D. Auricular acupuncture: A novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer. BJU Int 2009;103:186-190.
59. Cho SH, Whang WW. Acupuncture for vasomotor menopausal symptoms: A systematic review. Menopause 2009;16:1065-1073.
60. Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw 2010;8:1171-1179.
61. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: Position statement of The North American Menopause Society. Menopause 2004;11:11-33.
62. Booth-LaForce C, Thurston RC, Taylor MR. A pilot study of a Hatha yoga treatment for menopausal symptoms. Maturitas 2007;57:286-295.
63. Chattha R, Raghuram N, Venkatram P et al. Treating the climacteric symptoms in Indian women with an integrated approach to yoga therapy: A randomized control study. Menopause 2008;15:862-870.
64. Lee MS, Kim JI, Ha JY et al. Yoga for menopausal symptoms: A systematic review. Menopause 2009;16:602-608.
65. Lindh-Astrand L, Nedstrand E, Wyon Y et al. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas 2004;48:97-105.
66. Ueda M. A 12-week structured education and exercise program improved climacteric symptoms in middle-aged women. J Physiol Anthropol Appl Human Sci 2004;23:143-148.
67. Aiello EJ, Yasui Y, Tworoger SS et al. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause 2004;11:382-388.
68. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushesevaluation by ambulatory monitoring. Am J Obstet Gynecol 1992; 167:436-439.
69. Nedstrand E, Wijma K, Wyon Y et al. Applied relaxation and oral estradiol treatment of vasomotor symptoms in postmenopausal women. Maturitas 2005;51:154-162.
70. Tremblay A, Sheeran L, Aranda SK. Psychoeducational interventions to alleviate hot flashes: A systematic review. Menopause 2008; 15:193-202.